Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rami Komrokji

Showing results (61-70 of 129) with videos related to

Pageof 13
Sort By:
Leukemia Research|June 11, 2016
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemiaJulio C Chavez, Miguel Piris-Villaespesa, Samir Dalia, et al.
Leukemia Research|May 15, 2020
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancyChetasi Talati, Aaron D Goldberg, Amanda Przespolewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2019
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid LeukemiaKendra Sweet, Rami Komrokji, Eric Padron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2014
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromesGuillermo Garcia-Manero, Hanna J Khoury, Elias Jabbour, et al.
JCO Precision Oncology|March 14, 2024
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With RuxolitinibAndrew T Kuykendall, Somedeb Ball, Barbara Mora, et al.
Annals of Hematology|March 28, 2025
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndromeGuillermo Garcia-Manero, Manila Gaddh, Uwe Platzbecker, et al.
Leukemia Research|July 30, 2019
Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC)Seongseok Yun, Rohit Sharma, Onyee Chan, et al.
Leukemia & Lymphoma|July 19, 2016
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomideDana E Rollison, Rami Komrokji, Ji-Hyun Lee, et al.
Leukemia & Lymphoma|June 4, 2011
Telomere length in myelodysplastic syndromesDana E Rollison, P K Epling-Burnette, Jong Y Park, et al.
Transplantation and Cellular Therapy|August 15, 2024
Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic SyndromesOmar Albanyan, Hany Elmariah, Denise Kalos, et al.
Pageof 13

Showing results (61-70 of 129) with videos related to

Sort By:
Pageof 13
Leukemia Research|June 11, 2016
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemiaJulio C Chavez, Miguel Piris-Villaespesa, Samir Dalia, et al.
Leukemia Research|May 15, 2020
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancyChetasi Talati, Aaron D Goldberg, Amanda Przespolewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2019
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid LeukemiaKendra Sweet, Rami Komrokji, Eric Padron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2014
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromesGuillermo Garcia-Manero, Hanna J Khoury, Elias Jabbour, et al.
JCO Precision Oncology|March 14, 2024
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With RuxolitinibAndrew T Kuykendall, Somedeb Ball, Barbara Mora, et al.
Annals of Hematology|March 28, 2025
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndromeGuillermo Garcia-Manero, Manila Gaddh, Uwe Platzbecker, et al.
Leukemia Research|July 30, 2019
Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC)Seongseok Yun, Rohit Sharma, Onyee Chan, et al.
Leukemia & Lymphoma|July 19, 2016
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomideDana E Rollison, Rami Komrokji, Ji-Hyun Lee, et al.
Leukemia & Lymphoma|June 4, 2011
Telomere length in myelodysplastic syndromesDana E Rollison, P K Epling-Burnette, Jong Y Park, et al.
Transplantation and Cellular Therapy|August 15, 2024
Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic SyndromesOmar Albanyan, Hany Elmariah, Denise Kalos, et al.
Pageof 13